A Phase 1 Study of IPI-926 in Patients With Advanced and/or Metastatic Solid Tumor Malignancies
| Status: | Archived |
|---|---|
| Conditions: | Cancer |
| Therapuetic Areas: | Oncology |
| Healthy: | No |
| Age Range: | Any |
| Updated: | 7/1/2011 |
| Start Date: | September 2008 |
| End Date: | June 2011 |
The primary objectives of the study are:
- To determine the safety and the maximum tolerated dose (MTD) of IPI-926
- To examine the pharmacokinetic parameters of IPI-926 and its characterized major
metabolite(s)
- To recommend a dose and schedule of IPI-926 for subsequent studies
Study IPI-926-01 is a Phase 1, open-label, dose-escalation study in patients with advanced
and/or metastatic solid tumor malignancies.
We found this trial at
4
sites
Click here to add this to my saved trials
University of Colorado, Boulder As the flagship university of the state of Colorado, CU-Boulder is...
Click here to add this to my saved trials
Click here to add this to my saved trials
Click here to add this to my saved trials